Development of thermostable mRNA-based vaccines against the Delta variant of SARS-CoV-2

Certest Biotec is leading this cooperative project in partnership with Levprot Bioscience, Lev2050, 53biologics (BDI), and Innoup. The consortium is collaborating with the University of Zaragoza and the University of Navarra, collectively contributing their expertise and resources to drive this project's success.

The principal objective of the project is the development of a novel vaccine against the Delta variant of SARS-CoV-2 utilizing state-of-the-art messenger RNA (mRNA) technology. This novel vaccine aims not only to be highly effective in preventing the disease, but also to exhibit superior stability for long-term preservation compared to existing vaccines.

These breakthroughs will not only bolster Certest Biotec's mRNA vaccine platform but will also furnish invaluable insights for swift design and synthesis of vaccines targeting a range of infectious diseases. Furthermore, the advancements will pave the way for adapting this versatile platform to address other nucleic acid-based therapies, ushering in a new era of medical advancements.

STABVAC4COV is co-funded by the Centre for the Development of Industrial Technology (CDTI) with the support of the Spanish Ministry of Science and Innovation within the framework of the Missions Science and Innovation 2021 programme.



2.831.200,57 €

Execution period

09/2021 - 12/2023